Why Does Mounjaro Have an Extra Dose in Each Pen?

The misconception: many people assume there are five usable weekly doses

It is one of the questions our prescribers hear most weeks. Someone starts their first Mounjaro pen, counts five doses worth of medicine inside, and assumes they have a five-week supply. It is a completely logical reading of the situation. The pen does hold five doses of liquid. The label, though, says four weeks.

The truth is that the fifth portion of medicine has a job to do before the needle even reaches your skin. Pre-filled auto-injectors like the KwikPen require a priming mechanism: the first activation of the device pushes fluid through the internal pathway and into the needle, displacing any air and ensuring the delivery channel is fully loaded. Without that volume, the first recorded dose would be short. The extra dose is the engineering solution to that problem. It guarantees accuracy across all four injections by absorbing the dead-space and mechanical losses inside the device itself.

This is not unique to Mounjaro. Many pre-filled injection devices work the same way. The difference here is that the volume is large enough to register as a fifth dose-equivalent, which understandably creates confusion. The Mounjaro pen and its extra dose topic comes up often precisely because patients are paying close attention to their treatment, which is exactly what a good prescriber wants.

What the fifth dose actually contains, and why using it is not advisable

The fifth dose-equivalent is real medicine. It is not saline, not a placebo, not water. It is tirzepatide at the same concentration as the rest of the pen. What makes it different is that it is not reliably deliverable as a full, accurate injection. By the time the pen has dispensed four doses, the remaining volume is a combination of any residual fluid plus the amount the device needs to complete its mechanical cycle. The actual amount that could be expelled varies, and it will not consistently match the dose your prescriber has written for you.

Attempting an unplanned fifth injection from a pen that has already delivered four doses therefore carries two risks: an inaccurate dose and a departure from the prescribed schedule. Both matter for a medicine whose titration is carefully staged. Tirzepatide treatment starts at 2.5 mg precisely to let your system settle before the dose increases, skipping or distorting that schedule affects both tolerability and clinical outcomes. Your prescriber and the Patient Information Leaflet are the right sources for anything about how and when to inject. This page can explain the engineering; individual dosing decisions belong with your clinical team.

If you are trying to understand how titration works more broadly, the page on why Mounjaro doses increase over time covers the clinical rationale in detail.

How this affects what you receive and what to expect from each pen

In practical terms, each Mounjaro KwikPen gives you a four-week supply at a single dose strength. The pen arrives cold, in a plain unbranded box via DPD with a tracking number on your phone, refrigerate it promptly and it will be ready when you need it. The six available strengths (2.5 mg through to 15 mg) are each supplied in this same format, so as your dose is titrated upward you move to a new pen strength rather than using more doses from the current one.

The 5 mg pen, for example, contains five dose-equivalents of 5 mg tirzepatide; four are your injections and one absorbs the priming volume. The same logic applies at every rung of the schedule. What changes between pens is the concentration, not the architecture of the device.

Understanding this also resolves a related question: if the pen runs out after four injections and there is still some liquid visible, that remainder is the dead volume, not a missed dose. The pen is designed to stop dispensing at that point. You can find more about the physical design of the device on the page covering why the Mounjaro pen shows five doses.

For context on what private tirzepatide treatment costs in the UK, the Mounjaro cost page sets out the market picture honestly, including what a transparent price should cover. For a fuller overview of the medicine itself, the Mounjaro treatment page covers licensing, eligibility and the clinical evidence. The NHS tirzepatide medicines page is also a reliable and plain-English reference for how the medicine works and what to watch for.

If you have questions that go beyond what a page can answer, a prescriber at nume reviews every consultation personally. There is no algorithm making clinical decisions here. Start your free consultation at our treatment page and a GPhC-registered prescriber will assess whether tirzepatide is right for you.